Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.

Frontiers in immunology - 1 Jan 2022

You Zhixuan, Lv Meng, He Xuanyu, Pan Yingqin, Ge Junfeng, Hu Xue, Zheng Yating, Huang Mengli, Zhou Chengzhi, You Changxuan

Abstract excerpt

Background: Nowadays, immunotherapy targeting immune checkpoint receptors is one of the cornerstones of systemic treatment in melanoma. Homologous recombination repair (HRR) is one of the DNA damage response (DDR) pathways, which has been proved to correlate with the efficacy of platinum-based chemotherapy, PARP inhibitor therapy, and immunotherapy in a variety of cancers. However, their predictive value of HRR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunologic Factors

Share to Immunotherapy

Share to Melanoma

Share to Mutation

Share to Recombinational DNA Repair

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35990677
DOI: 10.3389/fimmu.2022.871756
PMCID: PMC9381822

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.PMID 35990677Read ↗

Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.Semantic proximity Read ↗

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.Semantic proximity Read ↗

Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of HeterozygositySemantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Somatic mutations in homologous recombination pathway predict favourable prognosis after immunotherapy across multiple cancer typesSemantic proximity Read ↗

Somatic mutations in homologous recombination pathway predict favorable prognosis after immunotherapy across multiple cancer typesSemantic proximity Read ↗

The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses.Semantic proximity Read ↗

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

Interaction of molecular alterations with immune response in melanoma.Semantic proximity Read ↗

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.